Trends from the National Cancer Database show that the use of neoadjuvant systemic therapy (NST) has increased sharply over the past decade but not uniformly across cancer types or stages. Test your...
In this video, Brian M. Slomovitz, MD, discusses his recent study demonstrating a significant improvement in disease-free survival with pembrolizumab in patients with dMMR endometrial cancer. He explains...
According to research published in JAMA Surgery, missed opportunities for risk assessment and surgical prevention are common among ovarian cancer patients with high-grade serous cancer (HGSC). Take this...
Trends from the National Cancer Database show that the use of neoadjuvant systemic therapy (NST) has increased sharply over the past decade but not uniformly across cancer types or stages. Test your...
According to research published in JAMA Surgery, missed opportunities for risk assessment and surgical prevention are common among ovarian cancer patients with high-grade serous cancer (HGSC). Take this...
October is Breast Cancer Awareness Month. Swipe through this slideshow to explore our latest coverage highlighting the evolving science shaping breast cancer care today from approaches to surgery and...
Endometrial cancer risk can be influenced by genetic, hormonal, and metabolic factors, and understanding which can be crucial to prevention and early detection. Do you know the risk factors for endometrial...
Researchers recently published a survey that aimed at evaluating public awareness of postmenopausal bleeding as a symptom of endometrial cancer. Do you know the survey findings? Test your knowledge with...
In this video, Brian M. Slomovitz, MD, discusses his recent study demonstrating a significant improvement in disease-free survival with pembrolizumab in patients with dMMR endometrial cancer. He explains...
In this video, Christian Dagher, MD, discusses the results of his team's study comparing the oncologic outcomes associated with treatment of stage II endometrial cancer with minimally invasive surgery vs...